These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33807818)

  • 21. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
    Joudi M; Moradi Binabaj M; Porouhan P; PeyroShabany B; Tabasi M; Fazilat-Panah D; Khajeh M; Mehrabian A; Dehghani M; Welsh JS; Keykhosravi B; Akbari Yazdi A; Ariamanesh M; Ghasemi A; Ferns G; Javadinia SA
    Front Endocrinol (Lausanne); 2022; 13():798975. PubMed ID: 35299966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis.
    Rotshild V; Hirsh-Raccah B; Miskin I; Muszkat M; Matok I
    Sci Rep; 2021 Nov; 11(1):22777. PubMed ID: 34815503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland.
    Rzymski P; Zeyland J; Poniedziałek B; Małecka I; Wysocki J
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33919672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia.
    Petrović V; Vuković V; Marković M; Ristić M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population.
    Guzmán-Martínez O; Guardado K; de Guevara EL; Navarro S; Hernández C; Zenteno-Cuevas R; Montero H
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review.
    Amanzio M; Mitsikostas DD; Giovannelli F; Bartoli M; Cipriani GE; Brown WA
    Lancet Reg Health Eur; 2022 Jan; 12():100253. PubMed ID: 34729549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials.
    Kumar S; Saikia D; Bankar M; Saurabh MK; Singh H; Varikasuvu SR; Maharshi V
    Pharmacol Rep; 2022 Dec; 74(6):1228-1237. PubMed ID: 36342658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
    Bos R; Rutten L; van der Lubbe JEM; Bakkers MJG; Hardenberg G; Wegmann F; Zuijdgeest D; de Wilde AH; Koornneef A; Verwilligen A; van Manen D; Kwaks T; Vogels R; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; Li Z; Barouch DH; Vellinga J; Langedijk JPM; Zahn RC; Custers J; Schuitemaker H
    NPJ Vaccines; 2020; 5():91. PubMed ID: 33083026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.
    García-Montero C; Fraile-Martínez O; Bravo C; Torres-Carranza D; Sanchez-Trujillo L; Gómez-Lahoz AM; Guijarro LG; García-Honduvilla N; Asúnsolo A; Bujan J; Monserrat J; Serrano E; Álvarez-Mon M; De León-Luis JA; Álvarez-Mon MA; Ortega MA
    Vaccines (Basel); 2021 Apr; 9(5):. PubMed ID: 33925526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects.
    Fabricius D; Ludwig C; Scholz J; Rode I; Tsamadou C; Jacobsen EM; Winkelmann M; Grempels A; Lotfi R; Janda A; Körper S; Adler G; Debatin KM; Schrezenmeier H; Jahrsdörfer B
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
    Ikegame S; Siddiquey MNA; Hung CT; Haas G; Brambilla L; Oguntuyo KY; Kowdle S; Vilardo AE; Edelstein A; Perandones C; Kamil JP; Lee B
    Res Sq; 2021 Apr; ():. PubMed ID: 33851150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines.
    Karbiener M; Farcet MR; Zollner A; Masuda T; Mori M; Moschen AR; Kreil TR
    NPJ Vaccines; 2022 Feb; 7(1):22. PubMed ID: 35181655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.
    Marsh GA; McAuley AJ; Au GG; Riddell S; Layton D; Singanallur NB; Layton R; Payne J; Durr PA; Bender H; Barr JA; Bingham J; Boyd V; Brown S; Bruce MP; Burkett K; Eastwood T; Edwards S; Gough T; Halpin K; Harper J; Holmes C; Horman WSJ; van Vuren PJ; Lowther S; Maynard K; McAuley KD; Neave MJ; Poole T; Rootes C; Rowe B; Soldani E; Stevens V; Stewart CR; Suen WW; Tachedjian M; Todd S; Trinidad L; Walter D; Watson N; Drew TW; Gilbert SC; Lambe T; Vasan SS
    NPJ Vaccines; 2021 May; 6(1):67. PubMed ID: 33972565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
    Ikegame S; Siddiquey MNA; Hung CT; Haas G; Brambilla L; Oguntuyo KY; Kowdle S; Vilardo AE; Edelstein A; Perandones C; Kamil JP; Lee B
    medRxiv; 2021 May; ():. PubMed ID: 33821288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis.
    Sakuraba A; Luna A; Micic D
    Gastroenterology; 2022 Jan; 162(1):88-108.e9. PubMed ID: 34599933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis.
    Wu X; Xu K; Zhan P; Liu H; Zhang F; Song Y; Lv T
    BMC Infect Dis; 2024 Feb; 24(1):234. PubMed ID: 38383356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients.
    Raadsen MP; Visser C; Lavell AHA; van de Munckhof AAGA; Coutinho JM; de Maat MPM; GeurtsvanKessel CH; Amsterdam Umc Covid-S/Hcw Study Group ; Bomers MK; Haagmans BL; van Gorp ECM; Porcelijn L; Kruip MJHA
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines.
    Naranbhai V; Garcia-Beltran WF; Chang CC; Mairena CB; Thierauf JC; Kirkpatrick G; Onozato ML; Cheng J; St Denis KJ; Lam EC; Kaseke C; Tano-Menka R; Yang D; Pavlovic M; Yang W; Kui A; Miller TE; Astudillo MG; Cahill JE; Dighe AS; Gregory DJ; Poznansky MC; Gaiha GD; Balazs AB; Iafrate AJ
    medRxiv; 2021 Oct; ():. PubMed ID: 34671780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized predictions of adverse side effects of the COVID-19 vaccines.
    Jamshidi E; Asgary A; Kharrazi AY; Tavakoli N; Zali A; Mehrazi M; Jamshidi M; Farrokhi B; Maher A; von Garnier C; Rahi SJ; Mansouri N
    Heliyon; 2023 Jan; 9(1):e12753. PubMed ID: 36597482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population.
    Aijaz J; Hussain S; Naseer F; Kanani F; Anis S; Sarfaraz S; Saeed S; Farooq H; Jamal S
    Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.